TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31577036

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen with noninvasive ventilation (NIV)
Number of subjects: 641

Group type: COMPARATOR
Intervention: High-flow nasal oxygen alone
Number of subjects: 641
Study: 29104871

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overweight patients (BMI > 25 kg/m2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 20
Study: 25180558

Group type: EXPERIMENTAL
Intervention: Automated EEG biofeedback (AEB)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Clinician guided EEG biofeedback (CEB)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Additional therapy sessions (AT)
Number of subjects: 95
Study: 23809621

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 21136031

Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy for 3 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (routine treatment only)
Number of subjects: 43
Study: 19916293

Group type: EXPERIMENTAL
Intervention: Acupuncture (thick-needle subcutaneous penetration of Shendao (GV 11), retained for 4 h/time, once daily, 5 times/week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (Levocetirizine Hydrochloride tablets, 5 mg/time, once daily for first two weeks, then once every other day in the 3rd and 4th weeks, and once every 3 days in the last two weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between acupuncture and medication groups
Number of subjects: 60
Study: 17502627

Group type: EXPERIMENTAL
Intervention: Cisplatin alone
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy
Number of subjects: 526

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 526
Study: 15182272

Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg/puff, 12 puffs daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipratropium 20 microg/puff, 12 puffs daily
Number of subjects: 0
Study: 12362966

Group type: EXPERIMENTAL
Intervention: Motivational Interview (MI) session
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Role Induction (RI) session
Number of subjects: 126

Group type: COMPARATOR
Intervention: No-preparatory session (Control Group - CG)
Number of subjects: 126
Study: 9660095

Group type: EXPERIMENTAL
Intervention: 6 mg melatonin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 12 mg melatonin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Angiotensin II (4, 8 and 16 ng/kg/min)
Number of subjects: 18
Study: 8018001

Group type: EXPERIMENTAL
Intervention: Bisoprolol 2.5 mg/d and Hydrochlorothiazide 6.25 mg/d
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 6.25 mg/d
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Bisoprolol and Hydrochlorothiazide (various combinations)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study: 2642455

Group type: EXPERIMENTAL
Intervention: Doxorubicin + cyclophosphamide + BCG (DC + BCG)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Doxorubicin + cyclophosphamide + cisplatin (DCP)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Doxorubicin + cyclophosphamide + cisplatin + BCG (DCP + BCG)
Number of subjects: 185
Study: 789844

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 mug three times daily)
Number of subjects: 0
Study: 29543570

Group type: EXPERIMENTAL
Intervention: Rational suicide vignette
Number of subjects: 117

Group type: COMPARATOR
Intervention: Nonrational suicide vignette
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both groups (Rational and Nonrational)
Number of subjects: 117
Study: 28350640

Group type: EXPERIMENTAL
Intervention: Active Video Game (AVG) supplementation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 32
Study: 25314034

Group type: EXPERIMENTAL
Intervention: RME on second deciduous molars (GrE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: RME on first permanent molars (Gr6)
Number of subjects: 70
Study: 23586594

Group type: EXPERIMENTAL
Intervention: Self-management interactive support (SMIS) program
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 65
Study: 21877102

Group type: EXPERIMENTAL
Intervention: Dyskinetic PD subjects off L-dopa
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Non-dyskinetic PD subjects off L-dopa
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 29
Study: 18644069

Group type: EXPERIMENTAL
Intervention: epalrestat
Number of subjects: 504

Group type: COMPARATOR
Intervention: control
Number of subjects: 504
Study: 17191415

Group type: EXPERIMENTAL
Intervention: Araoye's criteria
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sokolow‐Lyon criteria
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cornell's criteria
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Romhilt‐Estes score
Number of subjects: 100

Group type: COMPARATOR
Intervention: Echocardiographic LVH
Number of subjects: 100
Study: 12551858

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Bx Velocity stenting (slow release)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Bx Velocity stenting (fast release)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Entire cohort
Number of subjects: 30
Study: 8550745

Group type: EXPERIMENTAL
Intervention: Sodium phosphate infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham infusion (sodium chloride)
Number of subjects: 11
Study: 1646724

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (3.0 g) with 5 mg glipizide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide (1.0 g) with 5 mg glipizide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (150 ml water with 5 mg glipizide)
Number of subjects: 0
Study: 6312664

Group type: EXPERIMENTAL
Intervention: Naloxone (opiate/opioid antagonist)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31925414

Group type: EXPERIMENTAL
Intervention: Medication adherence reminder and symptom management intervention using the Symptom Management Toolkit during eight automated telephone weekly calls.
Number of subjects: 127
Study: 31277181

Group type: EXPERIMENTAL
Intervention: Simulated directed-learning in a life-education intervention
Number of subjects: 54
Study: 29073928

Group type: EXPERIMENTAL
Intervention: Tubal ligation by minilaparotomy provided by clinical officers (COs)
Number of subjects: 1970

Group type: COMPARATOR
Intervention: Tubal ligation by minilaparotomy provided by assistant medical officers (AMOs)
Number of subjects: 1970
Study: 25105284

Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme (MDP)
Number of subjects: 349
Study: 24820145

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 20 mg/day for 3 months
Number of subjects: 90
Study: 21927938

Group type: EXPERIMENTAL
Intervention: Colpexin Sphere plus pelvic floor muscle exercise
Number of subjects: 91

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 91
Study: 19567688

Group type: EXPERIMENTAL
Intervention: Active offer of prenatal screening test
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Discussion opportunity with caregivers
Number of subjects: 59
Study: 17499292

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine gel instillation before periprostatic neurovascular bundle block
Number of subjects: 250

Group type: COMPARATOR
Intervention: Periprostatic neurovascular bundle block without lidocaine gel instillation
Number of subjects: 250
Study: 15350440

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) at a dose of 1.44 g/d (0.450 g/m² bid for children)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 93
Study: 11306154

Group type: EXPERIMENTAL
Intervention: didanosine (ddI) plus stavudine (d4T) plus efavirenz (EFV) followed by zidovudine (ZDV) plus lamivudine (3TC) plus abacavir (ABC) plus nelfinavir (NFV)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: didanosine (ddI) plus stavudine (d4T) plus nelfinavir (NFV) followed by zidovudine (ZDV) plus lamivudine (3TC) plus abacavir (ABC) plus efavirenz (EFV)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: didanosine (ddI) plus stavudine (d4T) plus efavirenz (EFV) plus nelfinavir (NFV) followed by zidovudine (ZDV) plus lamivudine (3TC) plus abacavir (ABC) plus saquinavir plus ritonavir
Number of subjects: 1000
Study: 11205489

Group type: EXPERIMENTAL
Intervention: EGCG 200 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polyphenon E 200 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EGCG 400 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polyphenon E 400 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EGCG 600 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polyphenon E 600 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EGCG 800 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polyphenon E 800 mg
Number of subjects: 20
Study: 9170990

Group type: EXPERIMENTAL
Intervention: In-home coaching intervention
Number of subjects: 200
Study: 8318879

Group type: EXPERIMENTAL
Intervention: Provider-delivered smoking cessation intervention
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care advice control condition
Number of subjects: 186
Study: 3552639

Group type: EXPERIMENTAL
Intervention: Monopolar electrocoagulation (EC group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional methods (control group)
Number of subjects: 37
Study: 30402864

Group type: EXPERIMENTAL
Intervention: Balloon-stent kissing technique + Rotational Wire (BSKT+RW)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Jailed wire technique (JWT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Jailed balloon technique (JBT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Balloon-stent kissing technique (BSKT)
Number of subjects: 80
Study: 27983689

Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A (100 units into each of the five lumbar extensor spinae muscles, total dose 500 to 1000 units)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A
Number of subjects: 37
Study: 25011722

Group type: EXPERIMENTAL
Intervention: MitraClip device (Abbott Vascular) for mitral regurgitation
Number of subjects: 351
Study: 22190441

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 91
Study: 20921430

Group type: EXPERIMENTAL
Intervention: Darusentan
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 849

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study: 18447940

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 15854167

Group type: EXPERIMENTAL
Intervention: Infliximab treatment (5 mg/kg for induction, plus two maintenance infusions 8 weeks apart)
Number of subjects: 14
Study: 12878616

Group type: EXPERIMENTAL
Intervention: Nitrous oxide with 1.5 MAC sevoflurane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrous oxide with 1.0 MAC sevoflurane
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air-nitrous oxide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mean HR and MAP
Number of subjects: 10
Study: 10235439

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4g daily for 12 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Corn oil (4g daily for 12 weeks)
Number of subjects: 57
Study: 8909067

Group type: EXPERIMENTAL
Intervention: Betel nut chewing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no betel nut chewing)
Number of subjects: 28
Study: 1858085

Group type: EXPERIMENTAL
Intervention: Inhaled 15-(s)-hydroxyeicosatetraenoic acid (15-HETE) 80 nmol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (sodium phosphate buffer)
Number of subjects: 10
Study: 30160043

Group type: EXPERIMENTAL
Intervention: 6 mg/d melatonin supplements
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27100127

Group type: COMPARATOR
Intervention: None community use
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Passive community use
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Both passive and active community use
Number of subjects: 399
Study: 24214797

Group type: EXPERIMENTAL
Intervention: Facecards
Number of subjects: 138

Group type: COMPARATOR
Intervention: No Facecards (Control)
Number of subjects: 138
Study: 22318996

Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza hydrophilic extract (SMHE) for 60 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 20659225

Group type: EXPERIMENTAL
Intervention: High FODMAP diet (50 g/day)
Number of subjects: 30
Study: 17965289

Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase inhibitor nitro‐L‐arginine methyl ester (L‐NAME) at doses of 0.5, 1, 2, and 4 mg/kg intravenously over 60 min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase inhibitor nitro‐L‐arginine methyl ester (L‐NAME)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (30 ml normal saline)
Number of subjects: 14
Study: 16310305

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 80
Study: 14572573

Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab maintenance therapy
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab maintenance therapy
Number of subjects: 573

Group type: COMPARATOR
Intervention: Single 5 mg/kg infliximab infusion (control group)
Number of subjects: 573
Study: 11021165

Group type: EXPERIMENTAL
Intervention: Clotting process evaluation
Number of subjects: 10
Study: 8958890

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (starting at 40 mg/day, reducing by 5 mg every other day)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Inhaled fluticasone propionate (2 mg daily)
Number of subjects: 413
Study: 1586049

Group type: EXPERIMENTAL
Intervention: Nasal oxygen at 3 L/min delivered by concentrator
Number of subjects: 51

Group type: COMPARATOR
Intervention: Room air at 3 L/min delivered by defective concentrator
Number of subjects: 51

Group type: COMPARATOR
Intervention: N/A (no gas therapy)
Number of subjects: 51
Study: 3857938

Group type: EXPERIMENTAL
Intervention: Intravaginal pessary of 3 mg prostaglandin E2 (PGE2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intracervical 5‐mm laminaria tent (LT)
Number of subjects: 40
Study: 30712148

Group type: EXPERIMENTAL
Intervention: E-cigarettes with nicotine salt formulations
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: myblu 40-mg nicotine salt formulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All tested e-cigarettes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All products tested
Number of subjects: 15
Study: 28844522

Group type: EXPERIMENTAL
Intervention: Customized Care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 60
Study: 27430941

Group type: EXPERIMENTAL
Intervention: Listening to 432 Hz music during endodontic treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: No music during endodontic treatment
Number of subjects: 100
Study: 24704126

Group type: COMPARATOR
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 230
Study: 22919757

Group type: EXPERIMENTAL
Intervention: High-dose Ganciclovir (7.5 mg/kg in inducement phase, 10 mg/kg in maintaining phase)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-dose Ganciclovir (5 mg/kg in inducement and maintaining phases)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low-dose Ganciclovir
Number of subjects: 37
Study: 20436079

Group type: EXPERIMENTAL
Intervention: N-terminal propeptide of collagen IIA (PIIANP) measured at baseline and 4 years
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: N-terminal propeptide of collagen IIA (PIIANP) in anti-CCP positive patients
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cross-linked C-telopeptide of collagen II (CTX-II) measured at baseline and 4 years
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Uncoupling index for cartilage collagen metabolism calculated from PIIANP and CTX-II measurements
Number of subjects: 160
Study: 18778469

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg od
Number of subjects: 309

Group type: COMPARATOR
Intervention: Rofecoxib 25 mg od
Number of subjects: 309
Study: 16171525

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-alpha alone (n = 19)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-alpha in combination with lamivudine (n = 35)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-alpha alone or in combination with lamivudine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy controls (n = 50)
Number of subjects: 54
Study: 11841050

Group type: EXPERIMENTAL
Intervention: Silymarin MZ-80 (150 mg t.i.d. per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10099926

Group type: EXPERIMENTAL
Intervention: Elite female orienteers
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 74
Study: 8525871

Group type: EXPERIMENTAL
Intervention: Encoding size dimension
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Encoding both dimensions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Encoding slow dimension
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Encoding fast dimension
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 10
Study: 2265044

Group type: EXPERIMENTAL
Intervention: 1 MAC isoflurane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1 MAC enflurane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1.8 MAC isoflurane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1.8 MAC enflurane
Number of subjects: 32

Group type: COMPARATOR
Intervention: isoflurane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1.8 MAC groups
Number of subjects: 32
Study: 229091

Group type: EXPERIMENTAL
Intervention: Elective brain irradiation (EBI) with 2400 rad whole brain in 8 fractions over 10 days (NSD = 1130 ret)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no EBI)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups received 4 drug chemotherapy (lomustine, methotrexate, cyclophosphamide, vincristine) and radiotherapy (3000 rad to primary chest lesion).
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Elective brain irradiation (EBI)
Number of subjects: 55
Study: 31317368

Group type: EXPERIMENTAL
Intervention: Viewing Internet results suggesting autism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viewing Internet results suggesting language delay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not viewing Internet results
Number of subjects: 0
Study: 29086498

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4901

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4901
Study: 25500100

Group type: EXPERIMENTAL
Intervention: Sublobar resection (SR) with brachytherapy
Number of subjects: 212

Group type: COMPARATOR
Intervention: Sublobar resection (SR)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Thoracotomy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: T1b tumors
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: VATS
Number of subjects: 212
Study: 23279003

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (Initial Responders)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (Initial Responders)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (Partial Responders)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (Partial Responders)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 753
Study: 22298147

Group type: EXPERIMENTAL
Intervention: Health-nutrition education and IFA pediatric tablet intervention with parental involvement
Number of subjects: 0
Study: 19623188

Group type: EXPERIMENTAL
Intervention: Intervention group (21 schools)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (21 schools)
Number of subjects: 42
Study: 16700770

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Lecturing
Number of subjects: 79
Study: 12650785

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. for 2 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus ranitidine 300 mg HS for 4 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg QAM and QHS for 2 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every 8 hours for 2 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study: 11242715

Group type: EXPERIMENTAL
Intervention: Triple therapy with Lansoprazole (30 mg once a day), Amoxycillin (500 mg three times a day), and Roxythromycin (150 mg twice a day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dual therapy with Lansoprazole (30 mg once a day) and Amoxycillin (500 mg three times a day)
Number of subjects: 25
Study: 8668506

Group type: EXPERIMENTAL
Intervention: Visual feedback on a correctly adjusted medium-sized figure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 0
Study: 1387500

Group type: EXPERIMENTAL
Intervention: Captopril 1 x 25 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ramipril 1 x 2.5 mg
Number of subjects: 34
Study: 6144456

Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 312

Group type: COMPARATOR
Intervention: 0.25 mg triazolam
Number of subjects: 312